Literature DB >> 1457271

Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers.

M C Pratt1, N J Lewis-Barned, R J Walker, R R Bailey, B I Shand, J Livesey.   

Abstract

The possibility that the ACE inhibitors, enalapril and captopril, may decrease plasma EPO concentrations was studied in a single-blind, cross-over study in 10 healthy volunteers. Plasma EPO concentrations, haemoglobin concentration, red blood cell count, plasma creatinine concentration and mean arterial pressure were measured at baseline and after 28 days treatment with both ACE inhibitors. A significant fall in mean plasma EPO concentration occurred with both ACE inhibitors and returned to baseline after stopping the drugs. It is likely that ACE inhibitors decrease EPO formation, by inhibition of angiotensin-II production. This effect could be important in patients with renal failure, renal transplantation or other chronic conditions with an associated anaemia. Haematological parameters should be monitored in such patients when they are treated with an ACE inhibitor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1457271      PMCID: PMC1381421          DOI: 10.1111/j.1365-2125.1992.tb05644.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  An in vivo effect of renin on erythropoietin formation.

Authors:  A B Gould; S A Goodman; D Green
Journal:  Lab Invest       Date:  1973-06       Impact factor: 5.662

2.  Studies on erythropoietic action of angiotensin II.

Authors:  K Nakao; T Shirakura; M Azuma; T Maekawa
Journal:  Blood       Date:  1967-05       Impact factor: 22.113

3.  Regulation of erythropoiesis.

Authors:  D G Nathan
Journal:  N Engl J Med       Date:  1977-03-24       Impact factor: 91.245

4.  Worsening of anemia induced by long-term use of captopril in hemodialysis patients.

Authors:  H Hirakata; K Onoyama; K Iseki; H Kumagai; S Fujimi; T Omae
Journal:  Am J Nephrol       Date:  1984       Impact factor: 3.754

5.  Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy.

Authors:  A L Kamper; O J Nielsen
Journal:  Scand J Clin Lab Invest       Date:  1990-10       Impact factor: 1.713

6.  Anemia and angiotensin-converting enzyme inhibition in renal transplant recipients.

Authors:  P C Sizeland; R R Bailey; K L Lynn; R A Robson
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

7.  High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril.

Authors:  F Fyhrquist; K Karppinen; T Honkanen; O Saijonmaa; K Rosenlöf
Journal:  J Intern Med       Date:  1989-10       Impact factor: 8.989

8.  Enalapril (MK-421) and the white cell count and haematocrit.

Authors:  G T Griffing; J C Melby
Journal:  Lancet       Date:  1982-06-12       Impact factor: 79.321

9.  Participation of the renin-angiotensin system in the captopril-induced worsening of anemia in chronic hemodialysis patients.

Authors:  H Hirakata; K Onoyama; K Hori; M Fujishima
Journal:  Clin Nephrol       Date:  1986-07       Impact factor: 0.975

10.  Interrelation of the renin system and erythropoietin in rats.

Authors:  A B Gould; S Goodman; R DeWolf; G Onesti; C Swartz
Journal:  J Lab Clin Med       Date:  1980-09
  10 in total
  24 in total

1.  Erythropoietin down-regulates proximal renal tubular reabsorption and causes a fall in glomerular filtration rate in humans.

Authors:  Niels Vidiendal Olsen; Niels-Jacob Aachmann-Andersen; Peter Oturai; Thor Munch-Andersen; Andreas Bornø; Carl Hulston; Niels-Henrik Holstein-Rathlou; Paul Robach; Carsten Lundby
Journal:  J Physiol       Date:  2010-08-19       Impact factor: 5.182

2.  Efficacy of enalapril after ineffective theophylline treatment on erythrocytosis after renal transplantation.

Authors:  T Yagisawa; H Toma; H Yaguchi; M Tomaru; Y Iijima; H Suzuki; T Nakada
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

3.  Angiotensin-converting enzyme is required for normal myelopoiesis.

Authors:  Chentao Lin; Vivekanand Datta; Derick Okwan-Duodu; Xu Chen; Sebastien Fuchs; Randa Alsabeh; Sandrine Billet; Kenneth E Bernstein; Xiao Z Shen
Journal:  FASEB J       Date:  2010-12-09       Impact factor: 5.191

Review 4.  Effects of recombinant human erythropoietin in normal humans.

Authors:  Carsten Lundby; Niels Vidiendal Olsen
Journal:  J Physiol       Date:  2010-08-31       Impact factor: 5.182

Review 5.  Treatment of anemia in heart failure: potential risks and benefits of intravenous iron therapy in cardiovascular disease.

Authors:  Qurat-ul-ain Jelani; Stuart D Katz
Journal:  Cardiol Rev       Date:  2010 Sep-Oct       Impact factor: 2.644

Review 6.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

7.  Do alterations of endogenous angiotensin II levels regulate erythropoietin production in humans?

Authors:  S Freudenthaler; P Benöhr; A Grenz; T Selzer; T Schmidt; K Mörike; H Osswald; C H Gleiter
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 8.  Anemia in Cardiovascular Disease: Marker of Disease Severity or Disease-modifying Therapeutic Target?

Authors:  Harsh Goel; Joshua R Hirsch; Anita Deswal; Saamir A Hassan
Journal:  Curr Atheroscler Rep       Date:  2021-08-10       Impact factor: 5.113

Review 9.  Approaches to the treatment of anaemia in patients with chronic heart failure.

Authors:  Clare L Murphy; John J V McMurray
Journal:  Heart Fail Rev       Date:  2008-04-08       Impact factor: 4.214

Review 10.  Antihypertensive medications and anemia.

Authors:  Domenic A Sica; Rosemarie Mannino
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-09       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.